Ethics declarations Conflict of interest The authors declare that they have no conflicts of interest
Key trial programs include SURMOUNT (tirzepatide for weight management, NEJM 2022), SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024), and STEP (semaglutide, NEJM 2021)
Ongoing monitoring Regular follow-up appointments allow your provider to track progress, adjust dosing, manage any side effects, and provide accountability and support
Ozempic, which was developed to fight diabetes but reached global popularity thanks to its weight-loss side effect, has become a significant revenue driver for Novo, with sales reaching 95.7 billion Danish crowns ($13.5 billion) in 2023
GHK-Cu is generally well tolerated when used under medical supervision
it has been tied to delta-wave EEG activity, neurotransmitter changes, motor recovery in rat stroke models, and HPA-axis signaling